SEP 29, 2019 02:57 PM PDT

CBD Alleviates Angelman Syndrome Seizures in Mice Trial

WRITTEN BY: Julia Travers

CBD has already been shown to be effective as an anti-anxiety, antipsychotic and anti-epileptic substance. Can it help youth and adults with a rare neurological condition?

Cannabidiol (CBD) can lessen seizure severity in mice that genetically model Angelman syndrome, a rare neurodevelopmental condition. This condition is characterized by brain rhythm dysfunction, intellectual disability, lack of speech and, in many cases, drug-resistant epilepsy. The effectiveness of CBD was tested by University of North Carolina at Chapel Hill (UNC) School of Medicine researchers.

In the lab of Ben Philpot, the team tested the effects of CBD on seizures, brain activity abnormalities and motor deficit in mice that genetically model Angelman syndrome. According to EurekAlert, the Philpot lab creates genetically modified mouse models of neurodevelopmental disorders and uses them to look for new treatments for diseases including Rett, Pitt-Hopkins and Angelman syndromes.

One injection of CBD was found to substantially lessen seizure severity, when the seizures were triggered by loud sound or elevated body temperature. A typical dose of 100 mg/kg of CBD did lead to mild mouse sedation, but it had minimal impact on their balance or coordination. And, CBD reinstituted normal brain rhythms.

"We're confident our study provides the preclinical framework necessary to better guide the rational development of CBD as a therapy to help lessen seizures associated with Angelman syndrome and other neurodevelopmental disorders," Bin Gu, PhD, first author and postdoctoral fellow in the Philpot lab, said.

"There is an unmet need for better treatments for kids with Angelman syndrome to help them live fuller lives and to aid their families and caregivers. Our results show CBD could help the medical community safely meet this need," Ben Philpot, PhD, said.

 

“Cannabidiol attenuates seizures and EEG abnormalities in Angelman syndrome model mice,” was published in the Journal of Clinical Investigation.

 

Article Source: EurekAlert, Journal of Clinical Investigation

 

About the Author
  • Julia Travers is a writer, artist and teacher. She frequently covers science, tech and conservation.
You May Also Like
NOV 20, 2019
Cannabis Sciences
NOV 20, 2019
Marijuana for Morning Sickness Not so Good if You're the Baby
A recent finding suggests that using marijuana to treat morning sickness may actually harm the developing brain of the fetus. This finding was present...
NOV 20, 2019
Cancer
NOV 20, 2019
Cancer Patients Increase Cannabis Use 118 Percent in Nine Years
Between 2005 and 2014, cancer patients increased their use of marijuana/ cannabis 114 percent, according to a new study from researchers at the University ...
NOV 20, 2019
Health & Medicine
NOV 20, 2019
Can CBD Be Used to Treat Anxiety?
A 2019 study published on the National Center for Biotechnology Information showed that Cannabidiol might benefit anxiety-related disorders.  The...
NOV 20, 2019
Cannabis Sciences
NOV 20, 2019
Hospitalization Rates Stable After Marijuana Legalization
A recent study found that hospital stay rates remained steady after recreational marijuana was legalized in Colorado. Colorado is one of nine states that h...
NOV 20, 2019
Drug Discovery & Development
NOV 20, 2019
Therapeutic To Treat The Detrimental Effects of Marijuana
As U.S. states continue to legalize the use of marijuana, so is the number of American women using cannabis before becoming pregnant and to treat morning s...
NOV 20, 2019
Cannabis Sciences
NOV 20, 2019
Stages of Cannabis Plant Growth
What are the stages of cannabis plant growth?  As cannabis becomes more widely used both medicinally and recreationally, its legal cultivation is on t...
Loading Comments...